Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar

被引：3
|
作者：
Pagnini, Cristiano [1 ]
Di Paolo, Maria Carla [1 ]
De Angelis, Giulia [1 ]
Torcolacci, Federica [1 ]
Milano, Michele [1 ]
Trinca, Daniela [1 ]
Porciello, Roberto [2 ]
Graziani, Maria Giovanna [1 ]
机构：
[1] S Giovanni Addolorata Hosp, Dept Gastroenterol & Digest Endoscopy, Rome, Italy
[2] S Giovanni Addolorata Hosp, Dept Dermatol, Rome, Italy
来源：
INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 08期
关键词：
infliximab biosimilar; CT-P13; BS2; Crohn's disease; psoriasis; IMMUNOGENICITY;
D O I：
10.1093/ibd/izaa128
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [21] IN PATIENTS WITH IBD SWITCHING FROM ORIGINATOR INFLIXIMAB (REMICADE) TO BIOSIMILAR INFLIXIMAB (CT-P13) IS SAFE AND EFFECTIVE
    Rahmany, S.
    Cotton, S.
    Garnish, S.
    Brown, M.
    Saich, R.
    Lloyd, D.
    Gordon, J. N.
    GUT, 2016, 65 : A89 - A89
  • [22] Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar
    Mahmmod, S.
    Schultheiss, J. P. D.
    Tan, A. C. I. T. L.
    Lutgens, M. W. M. D.
    Gilissen, L. P. L.
    Mahmmod, N.
    van der Meulen-de Jong, A. E.
    Dijkstra, G.
    van Bodegraven, A. A.
    Oldenburg, B.
    Fidder, H. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S316 - S317
  • [23] Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars
    Ruiz-Aguello, M. B.
    Maguregui, A.
    Martinez, A.
    Nagore, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S299 - S299
  • [24] A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's disease and ulcerative colitis
    Ben-Horin, S.
    Leszczyszyn, J.
    Dudkowiak, R.
    Lahat, A.
    Gawdis-Wojnarska, B.
    Pukitis, A.
    Horynski, M.
    Farkas, K.
    Kierkus, J.
    Kowalski, M.
    Ye, B. D.
    Reinisch, W.
    Lee, S. J.
    Kim, S. H.
    Kim, M. R.
    Kim, Y. A.
    Kim, H. N.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S021 - S022
  • [25] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) Over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13.
    不详
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3319 - 3319
  • [26] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
    Parigi, Tommaso Lorenzo
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
  • [27] Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
    Farkas, Klaudia
    Rutka, Mariann
    Balint, Anita
    Nagy, Ferenc
    Bor, Renata
    Milassin, Agnes
    Szepes, Zoltan
    Molnar, Tamas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (09) : 1257 - 1262
  • [28] Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis
    Gheorghe, Cristian
    Svoboda, Pavel
    Mateescu, Bogdan
    JOURNAL OF DRUG ASSESSMENT, 2019, 8 (01) : 129 - 134
  • [29] Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
    Fiorino, Gionata
    Begona Ruiz-Arguello, M.
    Maguregui, Ainara
    Nagore, Daniel
    Correale, Carmen
    Radice, Simona
    Gilardi, Daniela
    Allocca, Mariangela
    Furfaro, Federica
    Martinez, Antonio
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (03) : 601 - 606
  • [30] Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center
    Farkas, Klaudia
    Rutka, Mariann
    Ferenci, Tamas
    Nagy, Ferenc
    Balint, Anita
    Bor, Renata
    Milassin, Agnes
    Fabian, Anna
    Szanto, Kata
    Vegh, Zsuzsanna
    Kurti, Zsuzsanna
    Lakatos, Peter L.
    Szepes, Zoltan
    Molnar, Tamas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (11) : 1325 - 1332
12345